FDA regulation of stem-cell-based therapies

被引：264

作者：

Halme, Dina Gould ^{[1
]}

Kessler, David A. ^{[1
]}

机构：

[1] Univ Calif San Francisco, Sch Med, San Francisco, CA 94143 USA

来源：

NEW ENGLAND JOURNAL OF MEDICINE | 2006年 / 355卷 / 16期

关键词：

D O I：

10.1056/NEJMhpr063086

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

[No abstract available]

引用

页码：1730 / 1735

页数：6

共 22 条

[1] Clonally derived human embryonic stem cell lines maintain pluripotency and proliferative potential for prolonged periods of culture [J].

Amit, M ;

Carpenter, MK ;

Inokuma, MS ;

Chiu, CP ;

Harris, CP ;

Waknitz, MA ;

Itskovitz-Eldor, J ;

Thomson, JA .

DEVELOPMENTAL BIOLOGY, 2000, 227 (02) :271-278

[2]

[Anonymous], 2004, Handbook of Stem Cells

[3]

BACH FH, 1968, LANCET, V2, P1364

[4]

*DEP HLTH HUM SERV, MED PRIV NAT STAND P

[5]

Food and Drug Administration, 1997, PROP APPR REG CELL T

[6]

Food and Drug Administration, 2003, GUID REV INSTR TEMPL

[7]

*FOOD DRUG ADM, 2006, INDS APPR COMPL CGMP

[8]

*FOOD DRUG ADM, 2001, PHS GUID INF DIS ISS

[9]

*FOOD DRUG ADM, 1993, FED RED, V58, P53248

[10]

*FOOD DRUG ADM, 2004, GUID IND EL DET DON

← 1 2 3 →